Evidence map›Paper›PMID 42711710›Full record

ArticleMicrobial cell factories2026

High-cell-density Escherichia coli-based nanobody production: benchmarking of subcellular targeting, strain background and process development strategies.

Jan-Angelus Meyer, Marie Beneke, Sadija Altmüller, Alexander Reeb, Jannis Künzl, Nathalie Opilo, Theo Weise, Christos Gouloudis, Rebekka Biedendieck, Rainer Krull

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jan-Angelus MeyerInstitute of Biochemical Engineering, Technische Universität Braunschweig, Braunschweig, Germany.
Marie BenekeInstitute of Biochemical Engineering, Technische Universität Braunschweig, Braunschweig, Germany.
Sadija AltmüllerInstitute of Biochemical Engineering, Technische Universität Braunschweig, Braunschweig, Germany.
Alexander ReebInstitute of Biochemical Engineering, Technische Universität Braunschweig, Braunschweig, Germany.
Jannis KünzlInstitute of Biochemical Engineering, Technische Universität Braunschweig, Braunschweig, Germany.
Nathalie OpiloInstitute of Biochemical Engineering, Technische Universität Braunschweig, Braunschweig, Germany.
Theo WeiseInstitute of Biochemical Engineering, Technische Universität Braunschweig, Braunschweig, Germany.
Christos GouloudisIBA Lifesciences GmbH, Göttingen, Germany.
Rebekka BiedendieckBraunschweig Integrated Centre of Systems Biology (BRICS), Technische Universität Braunschweig, Braunschweig, Germany.
Rainer KrullInstitute of Biochemical Engineering, Technische Universität Braunschweig, Braunschweig, Germany. r.krull@tu-braunschweig.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNanobodies (NB) are compact single-domain antibody fragments with substantial diagnostic and therapeutic potential, but scalable microbial production under controlled bioreactor conditions remains insufficiently characterized. In this study a high-cell-density cultivation (HCDC) fed-batch process for an anti-human CD45 NB in Escherichia coli was established and evaluated how process parameters, host background, and subcellular targeting (cytoplasmic vs. periplasmic) affect yield and product quality including correct disulfide bond formation.

resultsUsing a two-stage design-of-experiments (DoE) strategy in 2 L stirred-tank bioreactors, OD

conclusionsHigh-cell-density fed-batch cultivations of E. coli can reach > 2.5 g L

Indexed as

Escherichia coliSingle-Domain AntibodiesBatch Cell Culture TechniquesBioreactorsHumansPeriplasmTemperatureSingle-Domain AntibodiesBioprocess optimizationCytoplasmic disulfide bond formationDesign of experimentsEscherichia coliHigh-cell-density fed-batch cultivationNanobody productionPeriplasmic expressionProtein secretionRecombinant protein productionThermal protein stabilityVHH single-domain antibody

Identifiers

PMID42711710
PMCPMC13551711

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.